Hexarelin vs Tesofensine
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone Peptides
HexarelinFat Loss & Metabolic
Tesofensine- Summary
- Hexarelin is a potent synthetic GHRP and the strongest GH secretagogue in its class per unit dose. It also exhibits unique cardioprotective properties through direct binding to cardiac CD36 receptors, independent of GH release. Its potency is balanced by a tendency to desensitize GH release with prolonged use, making cycling important.
- Tesofensine is a triple monoamine reuptake inhibitor (TMRI) that blocks reuptake of serotonin, dopamine, and norepinephrine. Originally developed for Alzheimer's and Parkinson's disease, it was repurposed as a potent weight loss agent after clinical trials demonstrated substantial fat loss via appetite suppression and increased energy expenditure.
- Half-Life
- ~70 minutes
- 8-10 days (exceptionally long; accumulates over weeks)
- Admin Route
- SubQ
- Oral
- Research
- —
- —
- Typical Dose
- 100–200 mcg
- 0.25-0.5 mg per day
- Frequency
- 2–3 times daily
- Once daily
- Key Benefits
- Strongest GH pulse per mcg among GHRPs
- Unique direct cardioprotective effects via CD36
- Increased IGF-1 and muscle anabolism
- Accelerated recovery from training
- Bone density support
- Anti-aging via GH axis
- Potential cardiac rehabilitation benefits
- Potent appetite suppression via triple monoamine reuptake inhibition
- Significant weight loss (8-12% body weight in phase II trials at 0.5 mg)
- Increases basal metabolic rate and energy expenditure
- Reduces fat mass preferentially over lean mass
- Potential cognitive benefit via dopaminergic and noradrenergic enhancement
- Longer half-life than sibutramine allows once-daily dosing
- Side Effects
- Water retention
- Elevated cortisol
- Elevated prolactin (more pronounced than other GHRPs)
- Receptor desensitization with continuous use
- +1 more
- Elevated heart rate and blood pressure (sympathomimetic)
- Dry mouth
- Insomnia and sleep disturbances
- Nausea
- +4 more
- Stacks With
- —
- —